Woody Joseph Fralin purchased $21K of RCEL

Woody Joseph Fralin purchased 5,200 shares of AVITA Medical, Inc. (RCEL) at $4.00 on 2026-06-09.

Original reporting
SEC EDGAR · Woody Joseph Fralin
Published Jun 11, 2026, 1:17 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 11, 2026, 1:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$RCEL
Neutral
medium confidence
Mentioned
$RCEL
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RCELNeutralLow
01

Why it matters

A director’s open-market purchase is incremental information about insider sentiment, but it does not provide new clinical, regulatory, financial, or deal catalysts.

02

Market read

Traders may note the buy as a minor sentiment input, but it is unlikely to drive a sustained repricing without additional company-specific catalysts.

03

What to watch

The filing notes no pre-arranged 10b5-1 plan, but the article provides no context on motivation, timing constraints, or whether other insiders/large holders acted similarly.

Relevance 4/10Novelty 8/10Timing: Filed 2026-06-10 for a 2026-06-09 insider buy

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for AVITA Medical, Inc.

Company-level read

Ticker impact

$RCELNeutralMedium confidence
Context

SEC Form 4 shows director Woody Joseph Fralin bought 5,200 shares of AVITA Medical (RCEL) for ~$20.8K on 2026-06-09.

Expected impact

Likely minimal near-term price impact; any effect would be sentiment-driven and short-lived.

Evidence & confidence

The disclosure is a small, non-10b5-1 purchase by a director; without accompanying operational/news catalysts, it rarely changes fundamentals.

Market effects

No direct sector read-through; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine liquidity/compensation-related and may not reflect a change in business outlook, especially at small dollar size.

Key entities

  • AVITA Medical, Inc.

    Subject of the Form 4 insider transaction; director Woody Joseph Fralin purchased shares.

  • Woody Joseph Fralin

    Director who reported an open-market purchase of 5,200 shares on 2026-06-09.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$RCELMed

Avita Medical Q3 Earnings Call Highlights

Avita Medical (RCEL) reported Q3 revenue of $600,000 for PermeaDerm, stable from Q2. Gross margin rose to 84%, and net loss narrowed to $6.2M. The company secured $10M in credit and alleviated going-concern doubts. RECELL revenue and manufacturing efficiencies drove improvements.

$RCELMed

AVITA Medical Reports Third Quarter Results

AVITA Medical, Inc. (RCEL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AVITA Medical Reports Third Quarter Results Delivers Strong Q3 With 53% Year-Over-Year Revenue Growth Raises Full Year 2026 Revenue Guidance VALENCIA, Calif., November 5, 2026 (GLOBE NEWSWIRE) — AVITA Medical ® , Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic a

$RCELMedAI 8/10

Avita Medical Raises 2026 Revenue Outlook as Q2 Sales Climb 18%

Avita Medical (NASDAQ:RCEL) reported Q2 net loss of $7.7M, nearly $3M better than Q1, with cash use down to $3.2M and cash of $11.1M at quarter end. The company raised its 2026 revenue outlook and said it is within Perceptive Advisors debt revenue covenants, including a $73M 2026 target. Q2 sales rose 18%.